Literature DB >> 9672205

A rapid assay of endotoxin in whole blood using autologous neutrophil dependent chemiluminescence.

A D Romaschin1, D M Harris, M B Ribeiro, J Paice, D M Foster, P M Walker, J C Marshall.   

Abstract

A rapid (30 min) whole blood assay for the detection of lipopolysaccharide (LPS) is described. This chemiluminescent (CL) assay utilizes the CR1 and CR3 receptor-induced oxidant production of polymorphonuclear leucocytes as a detection platform. The differential priming of neutrophils in whole blood by LPS-antibody complexes allows the specificity of the assay to be achieved. Oxidant released in response to complement opsonized zymosan results in luminol oxidation and subsequent light emission. This is dependent on heat labile putative complement proteins in the plasma. The assay consists of a control which measures baseline whole blood neutrophil oxidant production. The test assay contains murine monoclonal IgM antibody against the Lipid A epitope of LPS and measures the enhanced chemiluminescent response of the neutrophils in the presence of LPS-antibody complexes. Maximal sensitivity of the CL assay is dependent upon optimal antigen-antibody equivalence and duration of pre-incubation with the whole blood sample. The quantification of LPS is possible by inclusion of a positive control containing a maximally reactive LPS dose (800 pg/ml Escherichia coli 055:B5 LPS at an antibody concentration of 0.8 microg/assay). The CL assay is insensitive to variations in patient neutrophil concentration over a minimum range of 0.5 to 20 x 10(9) cells/l. The CL assay is widely reactive with the LPS of many strains of gram negative bacteria but not with the cell wall products of gram positive bacteria or Candida and Aspergillus. In comparison to acid extraction chromogenic LAL, the CL assay demonstrates superior recovery precision and accuracy in in vitro studies. This was reproducible over a wide range of LPS concentrations (0.017-1.6 EU/ml or 20-2000 pg/ml). This assay may be a clinically useful tool for the diagnosis of infection or endotoxin in patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9672205     DOI: 10.1016/s0022-1759(98)00003-9

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  33 in total

1.  Impact of Antibiotic Resistance on the Treatment of Gram-negative Sepsis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

Review 2.  Current and developing technologies for monitoring agents of bioterrorism and biowarfare.

Authors:  Daniel V Lim; Joyce M Simpson; Elizabeth A Kearns; Marianne F Kramer
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 3.  Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant?

Authors:  Robert S Munford
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

4.  Impact of hepatic clearance of endotoxin using endotoxin activity assay.

Authors:  Yukihiro Sanada; Koichi Mizuta; Taizen Urahashi; Yoshiyuki Ihara; Taiichi Wakiya; Noriki Okada; Naoya Yamada; Kentaro Ushijima; Shinya Otomo; Koichi Sakamoto; Yoshikazu Yasuda
Journal:  Hepatol Int       Date:  2011-07-06       Impact factor: 6.047

5.  Effect of empiric antibiotic treatment on plasma endotoxin activity in septic patients.

Authors:  F Mignon; M Piagnerelli; M Van Nuffelen; J L Vincent
Journal:  Infection       Date:  2014-01-28       Impact factor: 3.553

Review 6.  Endotoxemia-menace, marker, or mistake?

Authors:  Robert S Munford
Journal:  J Leukoc Biol       Date:  2016-07-14       Impact factor: 4.962

7.  Prevalence of endotoxemia after surgery and its association with ICU length of stay.

Authors:  Franco Valenza; Lorella Fagnani; Silvia Coppola; Sara Froio; Francesca Sacconi; Cecilia Tedesco; Micol Maffioletti; Marta Pizzocri; Valentina Salice; Maria Luisa Ranzi; Cristina Marenghi; Luciano Gattinoni
Journal:  Crit Care       Date:  2009-06-29       Impact factor: 9.097

8.  Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial.

Authors:  R Phillip Dellinger; Sean M Bagshaw; Massimo Antonelli; Debra M Foster; David J Klein; John C Marshall; Paul M Palevsky; Lawrence S Weisberg; Christa A Schorr; Stephen Trzeciak; Paul M Walker
Journal:  JAMA       Date:  2018-10-09       Impact factor: 56.272

9.  Combining intermediate levels of the Endotoxin Activity Assay (EAA) with other biomarkers in the assessment of patients with sepsis: results of an observational study.

Authors:  Arino Yaguchi; Junji Yuzawa; David J Klein; Munekasu Takeda; Tomoyuki Harada
Journal:  Crit Care       Date:  2012-05-18       Impact factor: 9.097

10.  Endotoxaemia is common in children with Plasmodium falciparum malaria.

Authors:  Peter Olupot-Olupot; Britta C Urban; Julie Jemutai; Julius Nteziyaremye; Harry M Fanjo; Henry Karanja; Japhet Karisa; Paul Ongodia; Patrick Bwonyo; Evelyn N Gitau; Alison Talbert; Samuel Akech; Kathryn Maitland
Journal:  BMC Infect Dis       Date:  2013-03-05       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.